Related Topics

    Rubnitz: News Releases & Feature Stories

    A new look at an old drug: Improving AML survival

    The quest to improve cure rates for children with acute myeloid leukemia (AML) got a boost recently from a St. Jude study that took a new look at an old drug.

    Drug offers promising approach to improve outcome for children with high-risk leukemia

    St. Jude Children’s Research Hospital leads study showing that a drug withdrawn from the market in 2010 may enhance the effectiveness of bone marrow transplants for select pediatric leukemia patients. (Dr. Jeffrey Rubnitz)

    Hitting out of the Rough - Brennan Simkins

    St. Jude helps budding golfer Brennan Simkins through his battle with a rare form of acute myeloid leukemia, which required four bone marrow transplants.

    Smarter use of existing treatment helps dramatically boost survival of young AML patients

    More individualized therapy and better supportive care helped push the survival for children with acute myeloid leukemia (AML) to 71 percent three years after diagnosis, according to new research led by St. Jude Children’s Research Hospital investigators and reported in the medical journal The Lancet Oncology.

    Study points to new role for donor natural killer cells

    Powerful but rare immune cells taken from a parent might provide a safe, effective and affordable approach to preventing cancer’s return in young patients with acute myeloid leukemia (AML), according to new St. Jude research.

    Better outcomes for pediatric AML

    Accurate prediction of treatment response and subsequent adjustment of therapy results in high remission rate and low treatment-related mortality.